Shots:

• Rigel to receive $125M up front and is also eligible to receive ~$835M as development- regulatory and commercial milestones as well as royalties- which will vary depending upon Rigel's clinical development investment
• Lilly to get an exclusive WW license to Rigel's RIPK1 inhibitors- including its R552 in all indications. The companies will co-develop R552 at specified contribution levels under which Lilly will be responsible for all costs of global commercialization & Rigel gets the right to co-commercialize R552 in the US
• Rigel will initiate P-II trials of R552 in 2021. Pursuant to the collaboration- Lilly will solely lead all clinical development of RIPK1 inhibitors in CNS diseases

 ­ Ref: PRNewswire | Image: ABC News